Search:

×
28
Jun

Posted on

Medherant expands management team as it moves into clinical development of its revolutionary TEPI Patch®

Medherant patch

Medherant Ltd, a University of Warwick spin-out company which joined Mercia Technologies’ portfolio of direct investments in September 2016, has made a number of exciting new appointments to its management team.

Medherant, a developer of novel transdermal drug delivery patch technology, has appointed Sally Waterman as Chief Operating Officer (COO), Angus Hone as Chief Financial Officer (CFO) and Sheryl Caswell as Head of Clinical Development. These appointments mark a significant expansion of the Company’s management team to support the business as it moves into clinical development and commercialisation of its ibuprofen TEPI Patch®.

Sally brings over 30 years’ experience in executive management in large pharma, small biotech/biopharma and contract service companies. Sally has held a wide variety of strategic and operational roles, including leading R&D, and involvement in two IPOs, numerous financing rounds and M&A. Prior to joining Medherant she was Senior VP Corporate Development at Abzena plc. She is currently the Chairman of OBN Ltd.

Angus has over 20 years’ experience in financial management in the pharmaceutical and life sciences sector with extensive CFO/COO experience in VC/PE-backed healthcare, medical diagnostics, life science and software technology companies. He comes to Medherant from Cascade BI, where he acted as Mentor to the CEO. Prior to this he spent 3 years at Enigma Diagnostics, initially as acting CFO and then as CEO.

Nigel Davis, CEO, commented, “I’m pleased to welcome Sally and Angus to the team as we start manufacturing our ibuprofen TEPI® Patches and move into clinical trials. Both are highly regarded industry professionals and will add expertise and capability to our management team.

He added: "We’re delighted that Sheryl will also be joining us at such an important time in the Company’s development. Sheryl has over 20 years’ experience leading clinical development programmes on a wide range of products including other ibuprofen products.”

Medherant’s next generation drug delivery platform, TEPI Patch®, is designed to address many of the disadvantages of previous transdermal drug delivery patches. It will enable a wider range of drugs to be delivered through the skin, including those that are unsuitable for oral administration, and improve the user experience. Medherant is initially using the technology to develop products for pain relief, the first of which will be an ibuprofen patch. The technology will enable controlled release of drugs for up to at least 24 hours.

Sheryl commented: “I am delighted to join Medherant to lead clinical development at this exciting time and look forward to initiation of the Company’s first clinical study. I believe the TEPI Patch® technology developed by Medherant will provide patients with a much-needed convenient dosing form for a wide range of drugs.”

Dr Nicola Broughton, Head of Universities at Mercia Technologies PLC, which invested in Medherant last year said: “It’s fantastic to see the senior team at Medherant expanding with new talent. This is a key time for the company as it moves into clinical trials and with the added expertise and valuable experience of Sheryl, Sally and Angus, the business is in an ideal position for its next phase of growth.”